Search results for "Therapeutics"

showing 10 items of 489 documents

The Post-Lockdown Era: What Is Next in Italy?

2020

The current outbreak of the COVID-19 infection, which started in December 2019 in Wuhan (China), was declared a pandemic by the World Health Organization (WHO) on the 11th of March, 2020.

Pharmacology2019-20 coronavirus outbreakOpinionCoronavirus disease 2019 (COVID-19)business.industrydiagnosisSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)infectious diseaselcsh:RM1-950COVID-19infectious diseasesVirologymortalitydiagnosilcsh:Therapeutics. PharmacologyautopsyMedicinePharmacology (medical)business
researchProduct

Medicinally Used Asarum Species: High-Resolution LC-MS Analysis of Aristolochic Acid Analogs and In vitro Toxicity Screening in HK-2 Cells

2017

Species of Asarum are used in traditional Chinese medicine and, similar to members of the genus Aristolochia, they contain aristolochic acid analogs (AAAs). These compounds are known for their nephrotoxic and carcinogenic effects. So far, the phytochemistry and nephrotoxicity of species of Asarum is not well studied. A high-resolution LC-MS-based metabolomic approach was used to study the phytochemical variation in medicinally used Asarum species. The cytotoxicity of the samples was assessed using human kidney (HK-2) cells. The majority of samples contained potentially nephrotoxic AAAs, including 9-methoxy aristolactam (AL) IV, AL I, and AL IV. These compounds were present in methanol as we…

PharmacologyAsarumlcsh:Therapeutics. Pharmacologynephrotoxicityaristolactamlcsh:RM1-950Pharmacology (medical)metabolomicsLC-MSFrontiers in Pharmacology
researchProduct

Efficacy of ruxolitinib retreatment in a patient with high-risk myelofibrosis using the international prognostic scoring system

2019

Primary myelofibrosis (PMF) is a myeloproliferative neoplasm in which clonal proliferation of hematopoietic stem cells and bone marrow fibrosis coexist.1 Patients may eventually die due to leukemic progression, which occurs in up to 20% of cases, or because of cardiovascular comorbidities or cytopenia, which causes susceptibility to infections and bleeding.2 Myelofibrosis diagnosis relies upon the evaluation of several clinical and laboratory criteria suggested by the World Health Organization (WHO) in 2016.3 The major mutations leading to myelofibrosis usually occur in the JAK2, CALR, and MPL genes. However, in almost 10% of the cases, none of the above-mentioned mutations can be detected …

PharmacologyCytopeniamedicine.medical_specialtyRuxolitinibbusiness.industryIPSSruxolitinibprimary myelofibrosilcsh:RM1-950Case ReportGeneral Medicinemedicine.diseaseDiscontinuationPolycythemia veralcsh:Therapeutics. PharmacologyInternational Prognostic Scoring SystemInternal medicinemedicineprimary myelofibrosisMolecular MedicineMyelofibrosisAdverse effectbusinessMyeloproliferative neoplasmmedicine.drugDrugs in Context
researchProduct

Dexlansoprazole Delayed Release: Pharmacotherapy of Erosive Esophagitis and GERD

2011

Dexlansoprazole MR is a modified release formulation of the R-enantiomer of lansoprazole, which employs a novel Dual Delayed Release (DDR) technology. Pharmacokinetic studies have shown that the DDR technology provides a two peaks drug release, accuring 1–2 hours and 4–5 hours after dosing, leading to an extended duration of therapeutic plasma drug concentrations compared with conventional delayed release lansoprazole. Dexlansoprazole MR 30 and 60 mg provided superior intragastric pH control compared to that obtained with lansoprazole 15 mg and 30 mg once daily dosing. Dexlansoprazole can be taken without regard to food. The drug has been shown to be as efficacious as lansoprazole in heali…

PharmacologyDrugmedicine.medical_specialtybusiness.industrymedia_common.quotation_subjectlcsh:RM1-950LansoprazolePharmaceutical ScienceGeneral Medicinemedicine.diseasePlaceboGastroenterologylcsh:Therapeutics. PharmacologyPharmacotherapyPharmacokineticsInternal medicineGERDmedicineDexlansoprazoleDosingbusinessmedia_commonmedicine.drugBiomedical engineeringClinical Medicine Insights: Therapeutics
researchProduct

Editorial: Environmental enrichment as a treatment? Epigenetic mechanisms, challenges and limitations

2021

PharmacologyEnvironmental enrichmentbusiness.industrytranslationalagingRM1-950Computational biologyDNAenvironmental enrichment (EE)aging; DNA; environmental enrichment (EE); epigenetic; translational; treatment strategiestreatment strategiesMedicineTreatment strategyPharmacology (medical)Therapeutics. PharmacologyEpigeneticsbusinessepigenetic
researchProduct

The Crosstalk Between Signaling Pathways and Cancer Metabolism in Colorectal Cancer.

2021

Colorectal cancer (CRC) is one of the most frequently diagnosed cancers worldwide. Metabolic reprogramming represents an important cancer hallmark in CRC. Reprogramming core metabolic pathways in cancer cells, such as glycolysis, glutaminolysis, oxidative phosphorylation, and lipid metabolism, is essential to increase energy production and biosynthesis of precursors required to support tumor initiation and progression. Accumulating evidence demonstrates that activation of oncogenes and loss of tumor suppressor genes regulate metabolic reprogramming through the downstream signaling pathways. Protein kinases, such as AKT and c-MYC, are the integral components that facilitate the crosstalk bet…

PharmacologyGlutaminolysisCancercolorectal cancerprotein kinaseRM1-950Tumor initiationReviewBiologymedicine.diseasedigestive system diseasessignaling pathwaysMetastasisCrosstalk (biology)Cancer cellCancer researchmedicinemetabolic reprogrammingPharmacology (medical)Therapeutics. PharmacologySignal transductionReprogrammingmetabolismFrontiers in pharmacology
researchProduct

Targeting Oxidative Stress as a Therapeutic Approach for Idiopathic Pulmonary Fibrosis

2022

Idiopathic pulmonary fibrosis (IPF) is a chronic interstitial lung disease characterized by an abnormal reepithelialisation, an excessive tissue remodelling and a progressive fibrosis within the alveolar wall that are not due to infection or cancer. Oxidative stress has been proposed as a key molecular process in pulmonary fibrosis development and different components of the redox system are altered in the cellular actors participating in lung fibrosis. To this respect, several activators of the antioxidant machinery and inhibitors of the oxidant species and pathways have been assayed in preclinicalin vitroandin vivomodels and in different clinical trials. This review discusses the role of …

PharmacologyIPF—idiopathic pulmonary fibrosisantioxidant therapyfibrosisoxidative stressPharmacology (medical)Therapeutics. PharmacologyRM1-950Reviewrespiratory systemROS—reactive oxygen speciesrespiratory tract diseasesFrontiers in Pharmacology
researchProduct

Evaluation of the IKKβ Binding of Indicaxanthin by Induced-Fit Docking, Binding Pose Metadynamics, and Molecular Dynamics

2021

Background: Indicaxanthin, a betaxanthin belonging to the betalain class of compounds, has been recently demonstrated to exert significant antiproliferative effects inducing apoptosis of human melanoma cells through the inhibition of NF-κB as the predominant pathway. Specifically, Indicaxanthin inhibited IκBα degradation in A375 cells. In resting cells, NF-κB is arrested in the cytoplasm by binding to its inhibitor protein IκBα. Upon stimulation, IκBα is phosphorylated by the IKK complex, and degraded by the proteasome, liberating free NF-κB into the nucleus to initiate target gene transcription. Inhibition of the IKK complex leads to the arrest of the NF-κB pathway.Methods: To acquire deta…

PharmacologyMolecular modelChemistryAllosteric regulationIKKβMetadynamicsindicaxanthinInhibitor proteinRM1-950Settore CHIM/08 - Chimica Farmaceuticamolecular dynamicsIκBαchemistry.chemical_compoundanticancer activityProteasomeDocking (molecular)Settore BIO/10 - BiochimicaBiophysicsbinding pose metadynamicsPharmacology (medical)induced fit dockingTherapeutics. PharmacologyIndicaxanthinOriginal ResearchFrontiers in Pharmacology
researchProduct

COVID-19 and Periodontitis: A Dangerous Association?

2022

PharmacologyOpinionperiodontal infectionSARS-CoV-2periodontal diseaseCOVID-19Pharmacology (medical)Therapeutics. PharmacologyRM1-950periodontitisFrontiers in Pharmacology
researchProduct

Physicochemical stability of human insulin 1 I.U./mL infusion solution in 50 mL polypropylene syringes

2021

Abstract Objectives The objective of this study was to investigate the physicochemical stability of human insulin 1 I.U./mL injection solutions (Insuman® Rapid) diluted with 0.9% NaCl solution in 50 mL disposable three-piece polypropylene syringes and stored refrigerated or at room temperature. Methods 1 I.U./mL test solutions were prepared with Insuman® Rapid and 0.9% sodium chloride infusion solution in 50 mL Original-Perfusor® syringes and BD® Perfusion syringes. Test solutions were stored for 90 days at 2–8 °C/dark or 48 h at 20–25 °C/diffuse room light in order to determine chemical stability. Additional test solutions were stored 28 days at 2–8 °C/dark followed by 24 h at 20–25 °C/dif…

PharmacologyPolypropyleneChromatographyInternational unitphysicochemical stabilityInfusion solutionPharmacyRM1-950polypropylene syringechemistry.chemical_compoundchemistryHuman insulinhuman insulinPharmacology (medical)intravenous injectionTherapeutics. PharmacologyHD9665-9675Pharmaceutical industryPharmaceutical Technology in Hospital Pharmacy
researchProduct